NYMC Faculty Publications
DOI
10.1186/s40364-017-0088-5
Journal Title
Biomarker Research
First Page
5
Document Type
Article
Publication Date
2-1-2017
Department
Medicine
Abstract
CD20 negative B cell non-Hodgkin lymphoma (NHL) is rare and accounts for approximately 1-2% of B cell lymphomas. CD20- negative NHL is frequently associated with extranodal involvement, atypical morphology, aggressive clinical behaviour, resistance to standard chemotherapy and poor prognosis. The most common types of these include plasmablastic lymphoma, primary effusion lymphoma, large B-cell lymphoma arising from HHV8-associated multicentric Castleman's disease, and ALK+ large B cell lymphoma. This review provides an overview of the diagnostic and treatment modalities for CD20 negative B cell NHL.
Recommended Citation
Katchi, T., & Liu, D. (2017). Diagnosis and Treatment of CD20 Negative B Cell Lymphomas. Biomarker Research, 5, 5. https://doi.org/10.1186/s40364-017-0088-5
Publisher's Statement
Originally published in Biomarker Research 5:5. The original material can be found here.
Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.
